SpringerAuthorAcademy|1/17/19 |2
createdin2015– anewforceinpublishing
ProfessionalResearch Education
Revenues
1,048
328
315
1,661(€m)
3Divisions 13,000employees
390
Leadingbrandsandjournals
Notes: 2015financialsbasedonpreliminarynumbers.Segmentalfinancialsexcludingconsolidations.BasedonconstantFXratesofEUR/USD1.13.2014
divisionsplitbasedonPFcombinedSpringer&MSE.
Research
Professional
Education
Asia Pacific
c5900
Europec4700
Latin America
c950
North America
c950
Africac250
SpringerAuthorAcademy|1/17/19 |3
#1 journal publisher (over 3000 Journals)
#1 book publisher (around 200.000 eBooks)
#1 OA publisher (over 500 OA journals)
4 unique research databases
SpringerAuthorAcademy|1/17/19 |4
Ourwebsiteswww.springer.com
www.nature.com
www.authormapper.com
www.springerlink.com
www.springernature.com
SpringerAuthorAcademy|1/17/19 |5
21Nature-brandedresearchjournalsprovideprimaryresearchpapersalongwithreviews,newsandcommentariestokeepscientistsup-to-datewiththelatestdevelopmentsintheirfield
Nature-brandedresearchjournals
Physical Sciences
Life Sciences
SpringerAuthorAcademy|1/17/19 |6
17Nature-brandedreviewjournalsprovidereviewsofthelatestresearchpapersbyleadingexpertsinthefield.Papersarerigorouslyreviewedandeditedformaximumaccuracy.
Nature-brandedreviewjournals
Clinical Sciences
Life Sciences
SpringerAuthorAcademy|1/17/19 |7
Sincethebeginningofthe21stcentury,NaturelaunchednewjournalsinphysicalscienceslikeNatureNanotechnologyandNaturePhotonics
Since2015newjournalsexploringnewareas
Nature Reviews Disease Primers and our first review journals in Physical Sciences
Nature-branded research journals in new areas
And coming in 2017…
And 4 more journals coming in 2017…
SpringerAuthorAcademy|1/17/19 |8
NewjournalsfromNatureResearchin2018
NatureCatalysis willbringtogetherresearchersfromacrossallchemistryandrelatedfields,
publishingworkonhomogeneouscatalysis,heterogeneouscatalysis,andbiocatalysts,
incorporatingbothfundamentalandappliedstudies.Thejournalwillhaveaparticular
interestinappliedworkthatadvancesourknowledgeandinformsthedevelopmentof
sustainableindustriesandprocesses.
Assuch, NatureCatalysis willprovideessentialcoverageofthescienceandbusinessof
catalysisresearch,creatingauniquejournalforscientists,engineersandresearchersin
academiaandindustry.
www.nature.com/natcatal
Engineering&Electronics SocialSciences
Chemistry&MaterialsScienceEarth&EnvironmentalScience
• 3 new titles across the physical, life and social sciences
• Community centric, societally relevant journals that align to the UN’s Sustainable Development Goals
• Extending our expertise to engineering and social sciences
SpringerAuthorAcademy|1/17/19 |9
NatureSustainability isanewonline-onlyjournalthatwillpublishsignificantoriginal
researchfromabroadrangeofnatural,socialandengineeringfieldsaboutsustainability,its
policydimensionsandpossiblesolutions.Understandinghowtoensurehumanlifewill
thrivewithinthebiophysicallimitsoftheplanetistheoverarchinggoalofsustainability
research.
Partofthejournal'smissionistofacilitateacross-disciplinarydialoguearoundsustainability
issues,andnarrowthegapbetweenresearchandpolicymakingtoensurethereal-world
impactofresearch.
www.nature.com/natsustain
NewjournalsfromNatureResearchin2018
NatureElectronics willpublishbothfundamentalandappliedresearchacrossallareasofelectronics,fromthestudyofnovelphenomenaanddevices,tothedesign,constructionandwiderapplicationofelectroniccircuits.Itwillalsocovercommercialandindustrial
aspectsofelectronicsresearch.Atitscore,thejournalwillbeconcernedwiththedevelopmentofnewtechnologiesandunderstandingtheimpactofthesedevelopments
onsociety.
www.nature.com/natelectron
SpringerAuthorAcademy|1/17/19 |10
NatureMachineIntelligence
https://www.nature.com/natmachintell/
NatureMetabolism
https://www.nature.com/natmetab/
NatureReviewsPhysics
https://www.nature.com/natrevphys/
NaturejournalsfromNatureResearchin2019
SpringerAuthorAcademy|1/17/19 |12
Найтиправильныйжурнал
Сколько журналов существует?
Общееколичествожурналов
ЖурналыSpringer
Журналыоткрытогодоступа
Журналысиндексомнаучногоцитирования
>29,000
>2300
10,5861
87392
1. DOAJ.org(accessed29/5/15)
2. http://ip-science.thomsonreuters.com/cgi-bin/jrnlst/jlresults.cgi?PC=D(accessed29/5/15)
SpringerAuthorAcademy|1/17/19 |13
ВыборжурналавSpringerБесплатныйонлайнинструментдляпоиска
подходящихжурналов
Копируете и вставляете резюме статьи, система сама подбирает журнал
https://journalsuggester.springer.com/
SpringerAuthorAcademy|1/17/19 |14
ВыборжурналавSpringer
Рекомендуемые журналы
Фильтрацияпо:• Импакт фактор• Частотапубликации• Открытыйдоступ
SpringerAuthorAcademy|1/17/19 |15
ВыборжурналавSpringer
Целиизадачи,импакт-факторипериодичностьизданияжурнала
• Недавноопубликовано?• Цитируетсяввашем
документе?
SpringerAuthorAcademy|1/17/19 |16
Выбирайтежурналдонаписаниярукописи
Руководстводляавторов
• Структурарукописи• Количествослов• Стильссылок
Целиизадачи• Темы• Контингентчитателей• Будьтеуверены,что
подчеркнуть
SpringerAuthorAcademy|1/17/19 |17
Журналснизкимимпакт-фактором
Журналсвысокимимпакт-фактором
Небольшое дополнениексуществующимисследованиям
Новоеприложениедляранееопубликованных
материалов
Концептуальноепродвижение
Новыйматериалилиустройство
НовизнарезультатовНасколькоониновые?
SpringerAuthorAcademy|1/17/19 |18
Региональныйжурнал
Международныйжурнал
Результаты,имеющиелокальное значение
Выводы,применимыевовсеммире
Гдеониполезны?
Актуальностьрезультатов
SpringerAuthorAcademy|1/17/19 |19
Специализированныйжурнал
Журнал,ориентированный
наширокуюаудиторию
Результаты,применимыекконкретнойдисциплине
материаловедение
Результаты,применимыекнесколькимдисциплинам
материаловедение,экология,политика
Для когоониполезны?
Актуальностьрезультатов
SpringerAuthorAcademy|1/17/19 |20
Модельпубликации
Степеньдоступностижурнала?
Журнал
поподписке
Журнал
открытогодоступа
Еслистатьяинтереснатолькоученым, то
Еслистатьяинтереснакакученым,такиобщественности, то
SpringerAuthorAcademy|1/17/19 |22
Сопроводительноеписьмо – этопервоевпечатлениередакторовжурналововас
Важностьиактуальностьисследования
Подходитдляпубликациивихжурнале
Интереснодлячитателей?
SpringerAuthorAcademy|1/17/19 |23
Обязательнонеобходимонаписатьвпечатляющеесопроводительноеписьмо
Dear Dr Lippman,
Please find enclosed our manuscript entitled “Evaluation of the Glasgow prognostic score in patients undergoing curativeresection for breast cancer liver metastases,” which we would like to submit for publication as an Original Article in the BreastCancer Research and Treatment.
The Glasgow prognostic score (GPS) is of value for a variety of tumours. Several studies have investigated the prognostic value ofthe GPS in patients with metastatic breast cancer, but few studies have performed such an investigation for patients undergoingliver resection for liver metastases. Furthermore, there are currently no studies that have examined the prognostic value of themodified GPS (mGPS) in these patients. The present study evaluated the mGPS in terms of its prognostic value for postoperativedeath in patients undergoing liver resection for breast cancer liver metastases.
A total of 318 patients with breast cancer liver metastases who underwent hepatectomy over a 15-year period were included inthis study. The mGPS was calculated based on the levels of C-reactive protein and albumin, and the disease-free survival andcancer-specific survival rates were evaluated in relation to the mGPS. Prognostic significance was retrospectively analyzed byunivariate and multivariate analyses. Overall, the results showed a significant association between cancer-specific survival andthe mGPS and carcinoembryonic antigen level, and a higher mGPS was associated with increased aggressiveness of liverrecurrence and poorer survival in these patients.
This study is the first to demonstrate that the preoperative mGPS, a simple clinical tool, is a useful prognostic factor forpostoperative survival in patients undergoing curative resection for breast cancer liver metastases. This information isimmediately clinically applicable for oncologists treating such patients. As a premier journal covering the broad field of cancer,we believe that the Breast Cancer Research and Treatment is the perfect platform from which to share our results with theinternational medical community.
Датьинформацию
обисследовании
Описатьчтобылосделаноирезультаты
Описатьинтересдлячитателей
журнала
Имяредактора Названиеработы
Типстатьи
SpringerAuthorAcademy|1/17/19 |24
Экспертнаяоценка
Убедитьредакторажурнала,чтоработаподходит
Экспертнаяоценкаиисправления
Эффективноеинформированиередакторажурналаоб
исправлениях
SpringerAuthorAcademy|1/17/19 |25
Ответноеписьмо
Отвечатьнакомментариикаждогорецензента
HighlightthetextЛегкоувидетьизменения
Указыватьстрокуиномерстраницы
Использоватьразныецветашрифта
Выделитьтекст
Зачеркнутыйшрифтдляудалений
SpringerAuthorAcademy|1/17/19 |26
Комментарии рецензента: In your analysis of the data you havechosen to use a somewhat obscure fitting function (regression). Inmy opinion, a simple Gaussian function would have sufficed.Moreover, the results would be more instructive and easier tocompare to previous results.
Ответ:We agree with the reviewer’s assessment of the
analysis.
Согласиесрецензентом
Согласие
Почемувысогласныикакиеизменениявысделали?
SpringerAuthorAcademy|1/17/19 |27
Комментарий рецензента: In your analysis of the data youhave chosen to use a somewhat obscure fitting function(regression). In my opinion, a simple Gaussian function would havesufficed. Moreover, the results would be more instructive andeasier to compare to previous results.
Ответ: We agree with the reviewer’s assessment of theanalysis. Our tailored function, in its current form, makesit difficult to tell that this measurement constitutes asignificant improvement over previously reported values.We describe our new analysis using a Gaussian fitting inour revised Results section (Page 6, Lines 12–18)
Согласиесрецензентом
Согласие
Изменения
Местонахождения
Почемусогласны
SpringerAuthorAcademy|1/17/19 |28
Комментарий рецензента: In your analysis of the data youhave chosen to use a somewhat obscure fitting function(regression). In my opinion, a simple Gaussian function would havesufficed. Moreover, the results would be more instructive andeasier to compare to previous results.
Ответ: It is clear that this reviewer is not familiar with the
current analytical methods in the field. I recommend that you
identify a more suitable reviewer for my manuscript.
НесогласиесрецензентамиКакделатьнельзя:
SpringerAuthorAcademy|1/17/19 |29
Комментарий рецензентов: In your analysis of the data youhave chosen to use a somewhat obscure fitting function(regression). In my opinion, a simple Gaussian function would havesufficed. Moreover, the results would be more instructive andeasier to compare to previous results.
Ответ: Although a simple Gaussian fit would facilitatecomparison with the results of other studies, our tailored functionallows for the analysis of the data in terms of the Smith model[Robens et al., 2012]. We have now explained the use of thisfunction and the Smith model in our revised Discussionsection(Page 12, Lines 2–6).
Несогласиесрецензентамидопустимоввежливойформе:
Доводы
Изменения
Местонахождения
SpringerAuthorAcademy|1/17/19 |30
УлучшитьчитаемостьтекстаИспользуйтекороткиепредложения
Ограничитьколичествословвпредложенийдо15-20слов
Однаидеявпредложении
ИспользуйтеактивныйзалогКакоепредложениепрощедлявосприятия?
Пассивныйзалог:ThemodelscomparingtheeconomicgrowthanddiversificationoftheMiddleEastandEastAsiawereevaluated.Активныйзалог:We evaluated the models comparing the economic growth anddiversification of the Middle East and East Asia.
SpringerAuthorAcademy|1/17/19 |31
Структурапредложения
Ключеваяинформациярасполагаетсявконцепредложения.Читателивбольшестепени
обратятнанеевнимание.
1. Вызаслуживаетеповышениязаработнойплаты,нобюджетограничен
Вкакомпредложенииговоритсяотом,чтовыполучитеповышение?
2. Бюджетограничен,новызаслуживаетеповышениязаработнойплаты.
http://writingcenter.unc.edu/handouts/flow/
Акцентируйте
SpringerAuthorAcademy|1/17/19 |32
Используйтесильныеглаголы
Избегайтеноминализаций
Преобразованиеглаголавсуществительное
Estimate Estimation
Decide Decision
Confirm Confirmation
SpringerAuthorAcademy|1/17/19 |33
Используйтесильныеглаголы
We investigated if TiO2 surface modification improved catalytic efficiency and reduced cost.
24 слова
12слов
We performed an analysis to investigate if TiO2 surface modification led to an improvement in
catalytic efficiency and resulted in a reduction in cost.
SpringerAuthorAcademy|1/17/19 |35
Название должнопривлечьвниманиечитателя
Важныемоменты
ü Краткоеизложениеключевыхвыводов
ü Содержитключевыесловаü Менее20слов
Избегайте
Названиедолжнобытькраткимрезюменаиболееважныхвыводов
ВопросыОписаниеметодовАббревиатуры“Новый”или “ранеенесуществовавший”
SpringerAuthorAcademy|1/17/19 |36
Название – Хорошийпример
TiO2 surface modification improves microbial filtration of water treatment membranes
Содержитрелевантнуюинформацию
SpringerAuthorAcademy|1/17/19 |37
Аннотация – Первоевпечатлениеовашейработе
Цели
Результаты
Заключение
Важность вашейтемы
Значение вашегоисследования
Актуальность вашегоисследования
Ясностьвашегописьма
SpringerAuthorAcademy|1/17/19 |38
Аннотация
Цели
Общаяинформация
Методы
Результаты
Заключение
Почемупроводилосьисследование
Вашагипотеза
Методы/анализ
Наиболееважныевыводы
Заключение/выводы
Краткоеизложениевашейработы
SpringerAuthorAcademy|1/17/19 |39
Структурааннотации
Modifiedfrom:Cannegieter etal.Blood.2015;125:229‒235.
Numerous systemic treatment options exist for patients with mycosis fungoides (MF) and Sézary syndrome (SS); however, the comparative efficacy of these treatments is unclear. We performed a retrospective analysis of our cutaneous lymphoma database to evaluate the treatment efficacy of 198 MF/SS patients undergoing systemic therapies. The primary end point was time to next treatment (TTNT). Patients with advanced-stage disease made up 53%. The median follow-up time from diagnosis for all alive patients was 4.9 years (range 0.3‒39.6), with a median survival of 11.4 years. Patients received a median of 3 lines of therapy (range 1‒13), resulting in 709 treatment episodes. Twenty-eight treatment modalities were analyzed. We found that the median TTNT for single- or multiagentchemotherapy was only 3.9 months (95%confidence interval [CI] 3.2‒5.1), with few durable remissions. α-interferon gave a median TTNT of 8.7 months (95% CI 6.0-18.0), and histone deacetylase inhibitors (HDACi) gave a median TTNT of 4.5 months (95% CI 4.0‒6.1). When compared directly with chemotherapy, interferon and HDACi both had greater TTNT (P < .00001 and P =.01, respectively). In conclusion, this study confirms that all chemotherapy regimens assessed have very modest efficacy; we recommend their use be restricted until other options are exhausted.
Общаяинформация
Методы/цели
Результаты
Заключение
SpringerAuthorAcademy|1/17/19 |40
Структурааннотации
Modifiedfrom:Cannegieter etal.Blood.2015;125:229‒235.
Numerous systemic treatment options exist for patients with mycosis fungoides (MF) and Sézary syndrome (SS); however, the comparative efficacy of these treatments is unclear. We performed a retrospective analysis of our cutaneous lymphoma database to evaluate the treatment efficacy of 198 MF/SS patients undergoing systemic therapies. The primary end point was time to next treatment (TTNT). Patients with advanced-stage disease made up 53%. The median follow-up time from diagnosis for all alive patients was 4.9 years (range 0.3‒39.6), with a median survival of 11.4 years. Patients received a median of 3 lines of therapy (range 1‒13), resulting in 709 treatment episodes. Twenty-eight treatment modalities were analyzed. We found that the median TTNT for single- or multiagentchemotherapy was only 3.9 months (95%confidence interval [CI] 3.2‒5.1), with few durable remissions. α-interferon gave a median TTNT of 8.7 months (95% CI 6.0-18.0), and histone deacetylase inhibitors (HDACi) gave a median TTNT of 4.5 months (95% CI 4.0‒6.1). When compared directly with chemotherapy, interferon and HDACi both had greater TTNT (P < .00001 and P =.01, respectively). In conclusion, this study confirms that all chemotherapy regimens assessed have very modest efficacy; we recommend their use be restricted until other options are exhausted.
Почему вашеисследованиенеобходимо
Что высделали
Что выузнали
Какой вкладвнесетвашеисследованиевсферу